

Original Article



OPEN ACCESS

**Received:** Apr 6, 2017

**Revised:** Jun 22, 2017

**Accepted:** Aug 10, 2017

**Correspondence to**

**Wookjin Choi, MD**

Department of Emergency Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, 877, Bangeojinsunhwando-ro, Dong-gu, Ulsan 44033, Korea.  
E-mail: koreanermd@gmail.com

**Copyright** © 2017. The Korean Society of Cardiology

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

**ORCID iDs**

Yun Seok Kim ,  
<https://orcid.org/0000-0002-2817-557X>  
Yong Jik Lee ,  
<https://orcid.org/0000-0002-0837-4336>  
Ki-Bum Won ,  
<https://orcid.org/0000-0001-5502-9933>  
Jeong Won Kim ,  
<https://orcid.org/0000-0001-7986-9240>  
Sang Cjeol Lee ,  
<https://orcid.org/0000-0003-0502-1022>  
Chang-Ryul Park ,  
<https://orcid.org/0000-0003-2841-7046>  
Jong-Pil Jung ,  
<https://orcid.org/0000-0002-2992-7729>  
Wookjin Choi ,  
<https://orcid.org/0000-0001-8779-0081>

# Extracorporeal Cardiopulmonary Resuscitation with Therapeutic Hypothermia for Prolonged Refractory In-hospital Cardiac Arrest

Yun Seok Kim , MD<sup>1</sup>, Yong Jik Lee , MD<sup>1</sup>, Ki-Bum Won , MD<sup>2</sup>,  
Jeong Won Kim , MD<sup>3</sup>, Sang Cjeol Lee , MD<sup>1</sup>, Chang-Ryul Park , MD<sup>1</sup>,  
Jong-Pil Jung , MD<sup>1</sup>, and Wookjin Choi , MD<sup>4</sup>

<sup>1</sup>Department of Thoracic and Cardiovascular Surgery, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea

<sup>2</sup>Department of Cardiology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea

<sup>3</sup>Department of Thoracic and Cardiovascular Surgery, Andong Hospital, Andong, Korea

<sup>4</sup>Department of Emergency Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea

## ABSTRACT

**Background and Objectives:** We identified the impact of extracorporeal cardiopulmonary resuscitation (ECPR) followed by therapeutic hypothermia on survival and neurologic outcome in patients with prolonged refractory in-hospital cardiac arrest (IHCA).

**Methods:** We enrolled 16 adult patients who underwent ECPR followed by therapeutic hypothermia between July 2011 and December 2015, for IHCA. Survival at discharge and cerebral performance category (CPC) scale were evaluated.

**Results:** All patients received bystander cardiopulmonary resuscitation (CPR); the mean CPR time was 66.5±29.9 minutes, and the minimum value was 39 minutes. Eight patients (50%) were discharged alive with favorable neurologic outcomes (CPC 1–2). The mean follow-up duration was 20.1±24.3 months, and most deaths occurred within 21 days after ECPR; thereafter, no deaths occurred within one year after the procedure.

**Conclusion:** ECPR followed by therapeutic hypothermia could be considered in prolonged refractory IHCA if bystander-initiated conventional CPR is performed.

**Keywords:** Extracorporeal membrane oxygenation; Cardiopulmonary resuscitation; Hypothermia, induced

## INTRODUCTION

Many studies have shown that extracorporeal cardiopulmonary resuscitation (ECPR) has favorable outcomes for treating cardiac arrest, particularly in-hospital cardiac arrest (IHCA).<sup>1–7</sup> The overall rate of survival at discharge is 32–45%,<sup>1,7</sup> and a favorable neurologic outcome (cerebral performance category [CPC] of 1 or 2) rate of 77–100% has been reported among survivors.<sup>2–7</sup> Although these studies might have publication bias, and there is currently insufficient evidence to recommend routine ECPR for cardiac arrest, ECPR could potentially reverse cardiac arrest if it is rapidly implemented.<sup>8</sup> Some reports have shown that rapid implementation of ECPR was related to favorable outcomes.<sup>9–11</sup>

# Conflict of Interest

The authors have no financial conflicts of interest.

# Author Contributions

Conceptualization: Kim YS; Data curation: Lee YJ; Formal analysis: Won KB; Funding acquisition: none; Investigation: Kim JW; Methodology: Lee SC; Project administration: Choi W; Resources: none; Software: none; Supervision: Park CR, Jung JP; Validation: Choi W; Visualization: Won KB; Writing - original draft: Kim YS; Writing - review & editing: Choi W.

However, a dedicated ECPR team is essential for rapid implementation of ECPR. Ideally, the team should be available full-time in the hospital and respond immediately to ECPR calls. At our institution, there are unfortunately only 2 extracorporeal membrane oxygenation (ECMO) specialists and 2 perfusionists; therefore, they cannot respond immediately to all ECPR calls. In this circumstance, the duration of conventional cardiopulmonary resuscitation (CPR) is usually prolonged, without return of spontaneous circulation (ROSC). This scenario might be similar in other hospitals worldwide. Therefore, we reviewed the effects of ECPR for prolonged, refractory IHCA in order to evaluate the survival rate and neurologic outcome of these patients.

# METHODS

## Patients


A total of 82 patients underwent ECMO (CAPIOX EBS®; Terumo, Tokyo, Japan) at our institution between July 2011 and December 2015. Of these, 23 patients underwent ECPR for IHCA. Among these, we excluded 4 patients who received ECPR immediately after cardiac arrest, from an ECMO team that was already activated before the arrest occurred. We excluded another 3 patients who did not undergo subsequent therapeutic hypothermia. Finally, we identified 16 patients who met the enrollment criteria (**Figure 1**). The primary outcome of the study was in-hospital mortality, and the secondary outcome was 1-year survival.

This study was approved by our Ethics Committee/Institutional Review Board, which waived the requirement for informed patient consent because of the retrospective nature of the analysis.

## Treatment protocol

ECPR is indicated in suspected cardiac arrest if the following criteria are met: 1) age <75 years, 2) no-flow time <5 minutes, and 3) ROSC for less than 30 minutes without uncontrollable bleeding, previous severe neurologic deficit, previous end-stage organ failure, or current intracranial hemorrhage. These criteria are in alignment with current recommendations<sup>12-14)</sup> but are not an absolute indication.

Our ECPR team consists of one cardiac surgeon, one assistant (resident, intern, or nurse), and one perfusionist. They are not stationed in the hospital but are required to live within 30 minutes of the hospital. During CPR, an attending physician calls the cardiac surgeon to discuss whether



**Figure 1.** Enrollment criteria (July 2011 to December 2015).

ECMO = extracorporeal membrane oxygenation; ECPR = extracorporeal cardiopulmonary resuscitation.

ECPR should be performed, and the surgeon activates the team. While the team arrives, the physician obtains informed consent for ECPR from the patient's family, if available.

We routinely insert cannulas in the right femoral artery and vein using the percutaneous technique, with or without ultrasound guidance. We open the left inguinal area and expose the femoral vessels to insert the cannulas in cases of failed cannulation. After guide wire insertion, 3,000 units of unfractionated heparin are infused intravenously; cannulation is performed using an 18-Fr arterial cannula (OptiSite®; Edward Lifesciences, Irvine, CA, USA) and a 20-Fr venous cannula (VFEM®; Edward Lifesciences). The circuit is primed with normal saline and 1,000 units of unfractionated heparin during cannulation. A chest radiograph is used to monitor and adjust the venous cannula tip position at the level of the carina. Transthoracic echocardiography is performed when sufficient circulatory support is established, followed by a coronary angiography or a computed tomography scan, depending on the suspected cause of arrest.

ECMO target parameters include cases when: 1) the bypass flow is as high as possible if the drainage is adequate and the cardiac index is usually between 2.0 and 2.8 L/min/m<sup>2</sup>, 2) mean arterial pressure between 50 and 70 mmHg, 3) arterial pulse pressure >10 mmHg without left ventricular distension or pulmonary edema, and 4) decrease and normalization of serum lactate level. Activated clotting time is maintained between 160 to 200 seconds by adjusting the intravenous heparin infusion dose. However, in patients with active bleeding, heparin is discontinued until the bleeding is stopped. If the cannulated limb is pale, we insert a 5-Fr catheter at the cannulated superficial femoral artery for distal perfusion. In the case of pulmonary edema without pulse pressure, because of severe left ventricular dysfunction, an intravenous epinephrine infusion is added to facilitate ventricular contraction. Invasive procedures such as interatrial septostomy or left ventricular venting cannula insertion are not routinely performed to decompress the left ventricle for patients with contraindications.

Therapeutic hypothermia is routinely performed in unresponsive patients (Glasgow Coma Score ≤8) with IHCA treated with ECPR. The ECMO machine at our hospital (CAPIOX EBS®; Terumo) is not equipped with a cooling device, so patients are cooled with an endovascular cooling catheter (Alsium®; Zoll Medical Corp., Chelmsford, MA, USA) placed in the inferior vena cava via a femoral venous sheath or cooled with a surface cooling pad device (Arctic Sun®; Bard Medical, Louisville, CO, USA) applied to the patient's chest and limbs. The cooling procedure is initiated as soon as the catheter or cooling pad is installed and continued until the core body temperature reaches 34.5–35.0°C. The target temperature is 34.5°C to avoid overcooling and complications. Shivering during mild therapeutic hypothermia is evaluated using the Bedside Shivering Assessment Scale, and patients with a score >1 are treated with deeper sedation or with a bolus of intravenous meperidine and muscle relaxant in refractory cases.<sup>15)</sup> The core body temperature is recorded every hour with a thermometer at the tip of an esophageal probe. Hypothermia is maintained for 48 hours, and gradual rewarming is initiated. The target rate of rewarming is 0.5°C of temperature elevation every 12 hours.

ECMO flow is reduced gradually to 1 L/min and maintained for at least 12 hours when improved cardiac function is confirmed using a transthoracic echocardiography. Heparin treatment is discontinued, and the cannulas are removed after 4 to 6 hours if the patient is hemodynamically stable and the lactate level is not increasing. The cannulas are removed, and the sites are manually compressed for 1 hour if they are inserted percutaneously;

however, if the cannulas are inserted through skin incision, they are removed, and the femoral vessels are repaired surgically using 5-0 monofilament non-absorbable sutures.

### Statistical analysis

Categorical variables are presented as numbers and percentages and were compared using the  $\chi^2$  and Fisher's exact tests. Continuous variables are expressed as the mean $\pm$ standard deviation (SD) and were compared using Student's t-test or the Mann-Whitney U test. The survival rate was estimated with the Kaplan-Meier method. All reported p values were 2-sided, and  $p < 0.05$  was considered statistically significant. SPSS version 19 (SPSS Inc., Chicago, IL, USA) was used for statistical analyses.

## RESULTS

### Baseline patient characteristics

The baseline characteristics of the study population are shown in **Table 1**. One patient underwent off-pump coronary artery bypass (OPCAB) grafting 2 days prior to the procedure, for myocardial infarction. All patients received by-stander CPR, and the "no-flow" time (time between arrest and CPR start) was too short to measure. The mean "low-flow" time (time between CPR start and bypass start) was  $66.5 \pm 29.9$  minutes, and the minimum value was 39

**Table 1.** Baseline characteristics

Characteristics	All (n=16)	Survivors (n=8)	Non-Survivors (n=8)	p value
Age (years)	58.2 $\pm$ 12.4	55.6 $\pm$ 16.0	60.8 $\pm$ 7.4	0.247
Male sex	10 (62.5)	5 (62.5)	5 (62.5)	1.0
Body surface area (m <sup>2</sup> )	1.75 $\pm$ 0.19	1.76 $\pm$ 0.24	1.73 $\pm$ 0.13	0.713
Previous medical history				
Diabetes mellitus	4 (25.0)	2 (25.0)	2 (25.0)	1.0
Hypertension	6 (37.5)	2 (25.0)	4 (50.0)	0.608
COPD	0	-	-	-
Chronic liver disease	0	-	-	-
Chronic kidney disease	0	-	-	-
Coronary artery disease	6 (37.5)	3 (37.5)	3 (37.5)	1.0
ICMP	2 (12.5)	1 (12.5)	1 (12.5)	1.0
History of cardiac surgery	1 (6.3)	1 (12.5)	0	1.0
Witnessed CPR	16 (100)	-	-	-
Low-flow time*				
Total (minutes)	66.5 $\pm$ 29.9	63.3 $\pm$ 25.1	69.8 $\pm$ 35.5	0.600
Without any ROSC (minutes)	47.0 $\pm$ 9.8	44.4 $\pm$ 9.9	49.6 $\pm$ 9.7	0.208
Site of CPR start				0.057
Emergency department	6 (37.5)	5 (62.5)	1 (12.5)	
Catheterization room	6 (37.5)	2 (25.0)	4 (50.0)	
ICU	2 (12.5)	1 (12.5)	1 (12.5)	
OR	1 (6.3)	0	1 (12.5)	
General ward	1 (6.3)	0	1 (12.5)	
Initial rhythm				
VF	6 (37.5)	3 (37.5)	3 (37.5)	1.0
VT	10 (62.5)	5 (62.5)	5 (62.5)	1.0
Pulseless electrical activity	0	-	-	-
Peak serum pH	7.15 $\pm$ 0.14	7.18 $\pm$ 0.18	7.14 $\pm$ 0.09	0.343
Peak serum lactate (mmol/L)	11.2 $\pm$ 3.5	10.6 $\pm$ 4.3	11.8 $\pm$ 2.6	0.596
Peak serum creatinine (mg/dL)	1.40 $\pm$ 0.48	1.24 $\pm$ 0.26	1.56 $\pm$ 0.61	0.345
Peak serum troponin T (ng/mL)	11.0 $\pm$ 16.0	14.6 $\pm$ 20.6	7.5 $\pm$ 9.7	0.753

COPD = chronic obstructive pulmonary disease; CPR = cardiopulmonary resuscitation; ICMP = ischemic cardiomyopathy; ICU = intensive care unit; OR = operating room; ROSC = return of spontaneous circulation; VF = ventricular fibrillation; VT = ventricular tachycardia.

\*Time between CPR start and bypass start.

minutes. The emergency unit (n=6) and the angiography room (n=6) were the most frequent ECPR sites. Out of the 2 patients who received ECPR in the intensive care unit (ICU), one underwent a percutaneous coronary intervention (PCI) just before the arrest, and the other underwent OPCAB grafting 2 days before ECPR. One patient received ECPR in the operating room (OR) during the ventilator weaning period after a rotator-cuff surgery. He had received coronary stenting at the left anterior descending (LAD) branch 5 years prior to undergoing ECPR. In the general ward, one patient received CPR 18 days after a flap surgery for diabetic foot. This patient underwent balloon angioplasties on the left circumflex and right coronary arteries under CPR, followed by ECPR. The baseline characteristics were not different between survivors and non-survivors.

### Early outcomes and follow-up

Early outcomes are summarized in **Table 2**, and all patient clinical data are presented in **Table 3**. Myocardial infarction was the most common cause of arrest (87.5%). Mortality primarily occurred within the third day (75%) of ECPR. A total of 8 patients died before discharge (mortality group); among them, 7 patients died on ECMO. Of these 7 patients, 3 died on the day of ECPR, and another 3 died 2 or 3 days after the procedure. In the mortality group, a patient (patient 16, **Table 3**) died from uncontrollable bleeding from the sternotomy site that was made for central cannulation. The Methods section describes the frequency of

**Table 2.** Early ECPR IHCA outcomes

Outcomes	All (n=16)	Survivors (n=8)	Non-survivors (n=8)	p value
Cause of arrest				
Myocardial infarction	14 (87.5)	7 (87.5)	7 (87.5)	1
Left main culprit lesion	3 (18.8)	1 (12.5)	2 (25.0)	1
Multiple VD	12 (75.0)	5 (62.5)	7 (87.5)	0.569
Pulmonary embolism	1 (6.3)	1 (12.5)	0	1
Fulminant myocarditis	1 (6.3)	0	1 (12.5)	1
Concomitant procedure	15 (93.8)	7 (87.5)	8 (100.0)	1
PCI	13 (81.3)	6 (75.0)	7 (87.5)	
Pulmonary thrombolysis	1 (6.3)	1 (12.5)	0	
Temporary pacemaker	1 (6.3)	-	1 (12.5)	
LVEF after ECMO implantation	24.8±14.2	28.1±15.0	21.5±13.4	0.315
CRRT	10 (62.5)	3 (37.5)	7 (87.5)	0.119
ECMO duration (hours)	77.6±62.1	92.9±49.2	62.2±72.9	0.074
ECMO weaning off	9 (56.3)	8 (100.0)	1 (12.5)	<0.001
ICU stay (days)	11.6±10.2	17.3±9.8	5.9±7.2	0.013
Hospital stay (days)	36.3±50.8	67.6±56.8	4.9±7.1	0.002
CPC score 1-2	8 (50.0)	8 (100.0)	-	-
Causes of death				
No ROSB*	3 (18.8)	-	3 (37.5)	
Vasoplegia*	2 (12.5)	-	2 (25.0)	
Bleeding*	1 (6.3)	-	1 (12.5)	
Sepsis*	1 (6.3)	-	1 (12.5)	
Heart failure†	1 (6.3)	-	1 (12.5)	
Complications				
Chronic renal failure	1 (6.3)	1 (12.5)	0	1
Pneumonia	3 (18.8)	2 (25.0)	1 (12.5)	1
Bleeding	1 (6.3)	0	1 (12.5)	1
Limb ischemia	1 (6.3)	1 (12.5)	0	1
Limb contracture	3 (18.8)	3 (37.5)	0	0.2
Bed sore	1 (6.3)	1 (12.5)	0	1
New onset heart failure	2 (12.5)	2 (25.0)	0	0.467

CPC = cerebral performance category; CRRT = continuous renal replacement therapy; ECMO = extracorporeal membrane oxygenation; ECPR = extracorporeal cardiopulmonary resuscitation; ICU = intensive care unit; IHCA = in-hospital cardiac arrest; LVEF = left ventricular ejection fraction; PCI = percutaneous coronary intervention; ROSB = return of spontaneous beating; VD = vessel disease.


\*Death on ECMO; †death after ECMO weaning.

Table 3. Clinical data of all patients

Pt.	Age (years)	Sex	Diagnosis	Initial rhythm	pH*	Lactate*	Low-flow time (minutes)	Arrest locale	Bundle therapy	ECMO duration (hours)	ECMO wean off	CRRT	Pneumonia	New onset heart failure	Limb ischemia	Hospital stay (days)	Cause of death
Survival at discharge																	
1	38	M	AMI, 2VD	VT	7.24	5.6	83	ER	PCI	126	Y	N	N	Y	Y	155	
2	54	M	AMI, 1VD	VT	7.24	4.5	51	ER	PCI	9	Y	N	N	N	N	13	
3	45	M	AMI, LM 3VD	VT	6.97	9.5	42	ER	PCI	55	Y	N	N	N	N	17	
4	78	F	AMI, 3VD	VT	7.34	7.6	54	Angio	PCI	147	Y	N	Y	N	N	151	
5	71	F	AMI, 3VD	VF	7.15	15	43	Angio	PCI	142	Y	Y	Y	Y	N	58	
6	71	F	ICMP, AMI, LAD dissect	VF	7.38	14.5	102	ICU	OPCAB 2 days ago	70	Y	Y	N	N	N	72	
7	36	M	PTE	VT	6.85	15	92	ER	Pulmonary thrombolysis	124	Y	Y	N	N	N	54	
8	52	M	AMI, 1VD	VF	7.19	12.8	39	ER	PCI	70	Y	N	N	N	N	21	
Death before discharge																	
9	72	M	AMI, LM 3VD	VT	7.10	7.6	44	ICU	PCI	6	N	Y	N	N	N	1	Refractory VT
10	62	M	AMI, LM 2VD	VT	7.18	10.0	50	OR	PCI	62	N	Y	N	N	N	3	Vasoplegic shock
11	53	F	AMI, 3VD	VT	7.10	15.0	47	Angio	PCI	21	N	Y	N	N	N	1	Refractory VT
12	58	F	ICMP AMI, 3VD	VT	6.98	12.2	45	Angio	PCI	51	Y	Y	N	N	N	21	Heart failure
13	56	M	AMI, 2VD	VF	7.08	13.3	70	Ward	PCI	27	N	N	N	N	N	1	Refractory VF
14	58	M	AMI, 3VD	VF	7.30	9.5	135	Angio	PCI	237	N	Y	Y	N	N	9	Sepsis
15	72	M	AMI, 2VD	VT	7.16	11.7	52	Angio	PCI	43	N	Y	N	N	N	2	Vasoplegic shock
16	55	F	Fulminant myocarditis	VF	7.18	15.0	115	ER	Pacemaker	51	N	Y	N	N	N	2	Bleeding

AMI = acute myocardial infarction; Angio = angiography room; CRRT = continuous renal replacement therapy; ECMO = extracorporeal membrane oxygenation; ECPR = extracorporeal cardiopulmonary resuscitation; ER = emergency room; ICMP = ischemic cardiomyopathy; ICU = intensive care unit; LAD = left anterior descending; LM = left main disease; OPCAB = off-pump coronary artery bypass; OR = operating room; PCI = percutaneous coronary intervention; Pt. = patient; PTE = pulmonary thromboembolism; VD = vessel disease; VF = ventricular fibrillation; VT = ventricular tachycardia.

\*Worst value before ECPR.



**Figure 2.** Survival curve of patients who received ECPR for prolonged, refractory IHCA. ECPR = extracorporeal cardiopulmonary resuscitation; IHCA = in-hospital cardiac arrest.

procedures; invasive procedures such as central ECMO to decompress the left ventricle are not routinely performed in patients with contraindications. This patient, however, was alert and young (55-year-old) but showed pulmonary edema and limb ischemia on peripheral ECMO. Based on this, peripheral ECMO was replaced with central ECMO. Another 58-year-old female patient (patient 12, **Table 3**) with ischemic cardiomyopathy (ICMP) was rescued with ECPR and was weaned off ECMO 51 hours after. Twenty days later, however, she died from heart failure, and her family did not want further CPR to be performed.

Eight patients survived to discharge (survival group) with favorable neurologic outcomes (CPC 1–2). Of these, 7 patients had CPC 1. In the survival group, a patient (patient 1, **Table 3**) underwent fasciotomy followed by Achilles tendon lengthening because of limb ischemia, and another patient (patient 7, **Table 3**) underwent Achilles tendon lengthening alone because of ankle contracture. Two patients (patient 1 and 5, **Table 3**) experienced newly onset heart failure. Patient 5 died one year after discharge, and patient 1 is still alive 5 years after ECPR and waiting for heart transplantation.

The mean follow-up duration was  $20.1 \pm 24.3$  months, and one patient (patient 5, **Table 3**) died one year after discharge due to heart failure. Most mortality occurred between the day of and the 21st day after ECMO implantation, and no mortality occurred within 1 year after (**Figure 2**).

## DISCUSSION

We identified the impact of ECPR followed by therapeutic hypothermia on survival and neurologic outcome in patients with prolonged, refractory IHCA. Rates of survival and poor neurologic outcome of conventional CPR for patients with IHCA are currently low. Survival to discharge was 15%, and only 50% of these survivors had favorable neurologic outcomes (CPC scale 1 or 2).<sup>16)</sup> However, ECPR was associated with increased survival benefits compared with conventional CPR in patients with IHCA who received refractory to conventional CPR for more than 10 minutes.<sup>5)</sup>



Risk factors associated with in-hospital mortality in ECPR have been reported in previous studies, including initial rhythm as pulseless electrical activity or asystole, long “low-flow” time, low serum pH, and high serum lactate.<sup>13,4)</sup> In practice, however, these factors, with the exception of reducing the “low-flow” time, cannot be controlled by the ECMO team. Some reports have indicated that rapid implementation of ECPR can improve cardiac arrest outcomes and can be considered for potentially reversible cardiac arrest if rapidly implemented.<sup>8-11)</sup> Kim et al.<sup>17)</sup> reported that every 10-minute increment in low-flow time increased the rate of mortality by 5%, and an amount of time less than 60 minutes is important for improving survival outcomes. Based on these results, they recommended that the team and machine be prepared to respond rapidly to these events. In the real world, although it is necessary to have many specialists in the hospital for rapid ECPR implementation, most institutions cannot afford this staffing model. In these circumstances, the duration of “low-flow” time tends to be prolonged (66.5±29.9 minutes with a minimum of 39 minutes in our study), even if arrest occurs in the hospital, and it is very difficult to determine if ECPR should be performed.

A few studies have evaluated the use of therapeutic hypothermia in adult patients that receive ECPR.<sup>2,9,14,18)</sup> Based on these studies, therapeutic hypothermia as a bundle therapy is being established as a recommended procedure.<sup>19)</sup> However, the ideal target temperature, initiation, and duration of therapeutic hypothermia for treating patients who received ECPR for IHCA have not been well-established. We selected a target temperature of 34.5°C to avoid unexpected bleeding complications, while still maintaining the neuroprotective effect of mild therapeutic hypothermia.<sup>20)</sup>

In this study, we worked to reflect realistic clinical scenarios from team activation to the start of bypass and excluded 4 patients who received ECPR immediately after cardiac arrest from an ECMO team that was already activated before the arrest occurred. As mentioned previously, we have 2 ECPR teams, and each consists of one cardiac surgeon, one assistant (resident, intern, or nurse), and one perfusionist. The teams are not stationed in the hospital but live within 30 minutes travel time from the hospital. Under these circumstances, the “low-flow” time in our study was relatively long (66.5±29.9 minutes with a minimum of 39 minutes), but the rate of survival to discharge with a favorable neurologic outcome (50%) was comparable with other reports.<sup>1-5,9-11)</sup> In our experience, it usually takes about 20 minutes to prepare the machine and perform cannulation, but we were unable to measure the exact time because of insufficient medical records.

The most common cause of mortality was failure to achieve return of spontaneous beating after the bypass was started (37.5%). All of these patients (n=3) died within the first 27 hours after the procedure because heart transplantation or a ventricular assist device was not available, and there were no other options except termination of ECMO. The mean “low-flow” time in patients who died from failure to achieve return of spontaneous beating was 53.7±14.2 minutes, and this result was not significant compared with the mean “low-flow” time for the other patients (69.5±32.1 minutes). The severity and extent of myocardial damage are more important risk factors for failing to achieve return of spontaneous beating than the duration of “low-flow” time. However, we were unable to analyze this result because of the small population and retrospective design of this study.

As mentioned above, some risk factors associated with in-hospital mortality have been reported in previous studies, including initial rhythm as pulseless electrical activity or



asystole, long “low-flow” time, low serum pH, and high serum lactate.<sup>1)3)4)</sup> In our study, however, the severity of lactic acidosis and duration of “low-flow” time were not identified as risk factors for in-hospital mortality. This might be attributable to the small study population and retrospective design of this study.

This study is limited by the retrospective analyses of observational data and only included 16 patients and no control group, so a comparative study could not be performed. Therefore, these results did not completely show the effectiveness of therapeutic hypothermia or ECPR. The decision to implement ECPR was affected by the attending physician's preference, producing selection bias. Further prospective studies with larger cohorts are needed to confirm our results.

In conclusion, ECPR in combination with therapeutic hypothermia could be considered in prolonged refractory IHCA if bystander-initiated conventional CPR is performed, even if the team does not reside in the hospital.

## REFERENCES

1. Anselmi A, Flécher E, Corbineau H, et al. Survival and quality of life after extracorporeal life support for refractory cardiac arrest: a case series. *J Thorac Cardiovasc Surg* 2015;150:947-54.  
[PUBMED](#) | [CROSSREF](#)
2. Bednarczyk JM, White CW, Ducas RA, et al. Resuscitative extracorporeal membrane oxygenation for in hospital cardiac arrest: a Canadian observational experience. *Resuscitation* 2014;85:1713-9.  
[PUBMED](#) | [CROSSREF](#)
3. Haneya A, Philipp A, Diez C, et al. A 5-year experience with cardiopulmonary resuscitation using extracorporeal life support in non-postcardiotomy patients with cardiac arrest. *Resuscitation* 2012;83:1331-7.  
[PUBMED](#) | [CROSSREF](#)
4. Kagawa E, Inoue I, Kawagoe T, et al. Assessment of outcomes and differences between in- and out-of-hospital cardiac arrest patients treated with cardiopulmonary resuscitation using extracorporeal life support. *Resuscitation* 2010;81:968-73.  
[PUBMED](#) | [CROSSREF](#)
5. Chen YS, Lin JW, Yu HY, et al. Cardiopulmonary resuscitation with assisted extracorporeal life-support versus conventional cardiopulmonary resuscitation in adults with in-hospital cardiac arrest: an observational study and propensity analysis. *Lancet* 2008;372:554-61.  
[PUBMED](#) | [CROSSREF](#)
6. Chen JS, Ko WJ, Yu HY, et al. Analysis of the outcome for patients experiencing myocardial infarction and cardiopulmonary resuscitation refractory to conventional therapies necessitating extracorporeal life support rescue. *Crit Care Med* 2006;34:950-7.  
[PUBMED](#) | [CROSSREF](#)
7. Massetti M, Tasle M, Le Page O, et al. Back from irreversibility: extracorporeal life support for prolonged cardiac arrest. *Ann Thorac Surg* 2005;79:178-83.  
[PUBMED](#) | [CROSSREF](#)
8. Link MS, Berkow LC, Kudenchuk PJ, et al. Part 7: adult advanced cardiovascular life support: 2015 American Heart Association Guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. *Circulation* 2015;132:S444-64.  
[PUBMED](#) | [CROSSREF](#)
9. Stub D, Bernard S, Pellegrino V, et al. Refractory cardiac arrest treated with mechanical CPR, hypothermia, ECMO and early reperfusion (the CHEER trial). *Resuscitation* 2015;86:88-94.  
[PUBMED](#) | [CROSSREF](#)
10. Ryu JA, Cho YH, Sung K, et al. Predictors of neurological outcomes after successful extracorporeal cardiopulmonary resuscitation. *BMC Anesthesiol* 2015;15:26.  
[PUBMED](#) | [CROSSREF](#)
11. Kim SJ, Jung JS, Park JH, Park JS, Hong YS, Lee SW. An optimal transition time to extracorporeal cardiopulmonary resuscitation for predicting good neurological outcome in patients with out-of-hospital cardiac arrest: a propensity-matched study. *Crit Care* 2014;18:535.  
[PUBMED](#) | [CROSSREF](#)

12. Patel JK, Schoenfeld E, Parnia S, Singer AJ, Edelman N. Venoarterial extracorporeal membrane oxygenation in adults with cardiac arrest. *J Intensive Care Med* 2016;31:359-68.  
[PUBMED](#) | [CROSSREF](#)
13. Ortega-Deballon I, Hornby L, Shemie SD, Bhanji F, Guadagno E. Extracorporeal resuscitation for refractory out-of-hospital cardiac arrest in adults: a systematic review of international practices and outcomes. *Resuscitation* 2016;101:12-20.  
[PUBMED](#) | [CROSSREF](#)
14. Siao FY, Chiu CC, Chiu CW, et al. Managing cardiac arrest with refractory ventricular fibrillation in the emergency department: conventional cardiopulmonary resuscitation versus extracorporeal cardiopulmonary resuscitation. *Resuscitation* 2015;92:70-6.  
[PUBMED](#) | [CROSSREF](#)
15. Badjatia N, Strongilis E, Gordon E, et al. Metabolic impact of shivering during therapeutic temperature modulation: the Bedside Shivering Assessment Scale. *Stroke* 2008;39:3242-7.  
[PUBMED](#) | [CROSSREF](#)
16. Wang CH, Huang CH, Chang WT, et al. Associations among gender, marital status, and outcomes of adult in-hospital cardiac arrest: a retrospective cohort study. *Resuscitation* 2016;107:1-6.  
[PUBMED](#) | [CROSSREF](#)
17. Kim DH, Kim JB, Jung SH, Choo SJ, Chung CH, Lee JW. Extracorporeal cardiopulmonary resuscitation: predictors of survival. *Korean J Thorac Cardiovasc Surg* 2016;49:273-9.  
[PUBMED](#) | [CROSSREF](#)
18. Sakamoto S, Taniguchi N, Nakajima S, Takahashi A. Extracorporeal life support for cardiogenic shock or cardiac arrest due to acute coronary syndrome. *Ann Thorac Surg* 2012;94:1-7.  
[PUBMED](#) | [CROSSREF](#)
19. Pang PY, Wee GH, Hoo AE, et al. Therapeutic hypothermia in adult patients receiving extracorporeal life support: early results of a randomized controlled study. *J Cardiothorac Surg* 2016;11:43.  
[PUBMED](#) | [CROSSREF](#)
20. Rittenberger JC, Friess S, Polderman KH. Emergency neurological life support: resuscitation following cardiac arrest. *Neurocrit Care* 2015;23 Suppl 2:S119-28.  
[PUBMED](#) | [CROSSREF](#)